Genyro

Building biology at the rate of design.

[Genyro @Genyroinc]

Genyro is pleased to share a new publication in #NatureBiotechnology from co-founder Brian Hie and his colleagues Stanford University titled “Efficient Generation of Epitope-Targeted Antibodies with Germinal.”

Full paper: https://t.co/VFaUQqxh1O

[Genyro @Genyroinc]

Genyro’s co-founder and CEO Adrian Woolfson participated in the #FutureTrendsForum in Madrid last week, which explored the future of synthetic biology and how nations can position themselves at the forefront of this transformation.

[Genyro @Genyroinc]

We pleased to announce a new pre-print, just deposited in BioRxiv and medRxiv tited “Rapid in vitro synthesis of DNA templates via Sidewinder for polyadenylated Hantavirus mRNA vaccine candidates.”

Find the pre-print here: https://t.co/yUi0OEW5Ae

[Genyro @Genyroinc]

We are pleased to announce a new preprint published in BioRxiv. By using new design algorithm, #PyWinder, #Sidewinder utilizes single oligo pools to assemble 640 oligos in parallel with an unprecedented misconnection rate of 1 in 10,000,000. Preprint: https://t.co/1gtRb7Z3np

[Genyro @Genyroinc]

@Genyroinc CEO @AdrianWoolfson is happy to announce that the company he founded prior to @Genryo, @replaybio, has been acquired by @LEOHealthySkin for USD 50 million upfront, plus milestone payments, and tiered royalties.

[Genyro @Genyroinc]

Building biology at the rate of design.